Being on the cutting edge of biotechnology means doing something different than what everyone else is doing. It means providing solutions to problems that others cannot provided. In the U.S. alone, over 800,000 people work in the biopharmaceutical arena. But it is the Staff at Amicus Therapeutics, Inc. (Nasdaq:FOLD) that is making huge leaps in order to bring new and innovative therapies to the People around the World who need them the most.
With Headquarters in Cranbury, New Jersey, Amicus Therapeutics is constantly on the move to make a difference for those who need a solution most. They embody a risk-taking culture because that is what it takes to drive the type of innovation that is needed so badly in the biopharmaceutical arena. Conventional thinking and conventional decision making have not provided solutions to the many who suffer from rare and orphan diseases. Amicus Therapeutics looks at things differently by asking different questions, taking calculated risks, and never allowing themselves to be constrained by prior thinking.
The culture at Amicus Therapeutics really is driven from top leadership to all levels of the organization (GoogleFinance). Chairman and Chief Executive Officer, John F. Crowley, understands that it is the passion of the Staff that drives the innovation. The passion and drive have pushed several key therapies to the late development phases which are ready to burst from the pipeline. Treating rare conditions and diseases such as Fabry disease, Pompe disease, and other Lysosomal Storage Disorders (LSDs) has been our passion and we are ready for People around the globe to receive the benefits from our innovative therapies.
Science powered by passion is a constant theme embedded in the culture at Amicus Therapeutics. Using innovative technology to specifically target mutated proteins has allowed Amicus Therapeutics to enhance the treatment for those suffering from rare and orphan diseases.
At Amicus Therapeutics, the unified goal is to provide People around the world with solutions when they need them the most.